v3.26.1
Share-Based Compensation and Other Compensation Plans - Schedule of Long-Term Equity Incentive Awards Approved (Details) - shares
1 Months Ended
Jul. 31, 2025
Jul. 31, 2024
Performance Restricted Stock Units (at max) | Chief Executive Officer    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Granted (in shares)   14,450,000
Performance Restricted Stock Units (at max) | President and Chief Investment Officer    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Granted (in shares)   17,000,000
Performance Restricted Stock Units (at max) | President and Immunovant CEO    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based compensation arrangement by share-based payment award, number of shares authorized (in shares)   11,900,000
Performance Restricted Stock Units (at max) | President and Vant Chair    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Granted (in shares) 11,900,000  
Restricted Stock Units | Chief Executive Officer    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Granted (in shares)   2,754,821
Restricted Stock Units | President and Chief Investment Officer    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Granted (in shares)   1,836,547
Restricted Stock Units | President and Immunovant CEO    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Granted (in shares)   204,000
Restricted Stock Units | President and Vant Chair    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Granted (in shares) 1,836,547  
Stock Options | Chief Executive Officer    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Granted, stock options (in shares)   0
Stock Options | President and Chief Investment Officer    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Granted, stock options (in shares)   0
Stock Options | President and Immunovant CEO    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Granted, stock options (in shares)   409,000
Stock Options | President and Vant Chair    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Granted, stock options (in shares) 0